MetaCap

Insmed (INSM) vs Teva Pharmaceutical Industries (TEVA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Teva Pharmaceutical Industries (TEVA) has outperformed Insmed (INSM) over the past year, gaining 62.0% versus a loss of 28.9%. Over five years, INSM leads with a +388.5% price change compared with +362.1% for TEVA. Teva Pharmaceutical Industries is the larger company by market cap ($45.77 billion vs $31.01 billion), about 1.5 times the size, while Insmed is growing revenue faster (+66.7% vs +4.3%).

On valuation, Teva Pharmaceutical Industries trades at a lower forward P/E (12.5x vs 220.2x for Insmed). Teva Pharmaceutical Industries converts more of its revenue into profit, with a net margin of 8.2% versus -210.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INSM-28.89%TEVA+62.04%
+91%+15%-61%
Nov 21, 20251 yearNov 20, 2026
INSM+363.99%TEVA+341.78%
+614%+268%-77%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INSM versus TEVA key metrics
MetricINSMTEVA
Share price$141.33$39.23
Market cap$31.01B$45.77B
1-day change-2.17%+1.79%
YTD return-18.79%+25.70%
1-year return-28.89%+62.04%
5-year return+388.52%+362.07%
P/E ratio (TTM)—91.23
Forward P/E220.1812.53
EPS (TTM)$-2.81$0.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$606.42M$17.26B
Revenue growth (YoY)+66.73%+4.32%
Net income (latest FY)$-1.28B$1.41B
Gross margin79.73%51.79%
Operating margin-205.59%12.50%
Net margin-210.54%8.17%
52-week high$212.75$44.57
52-week low$90.39$24.34
Distance from 52-week high-33.57%-11.98%
Analyst consensusstrong_buybuy
Avg. price target upside+37.39%+28.19%
Average volume3.09M6.31M
Shares outstanding219.38M1.17B
Employees1,66431,173
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TEVA has outperformed INSM by 90.9 percentage points over the past year.
  • Teva Pharmaceutical Industries is more profitable, keeping 8.2 cents of every revenue dollar as net income versus -210.5 cents for Insmed.
  • Insmed grew revenue faster in its latest fiscal year (+66.73% vs +4.32%).

About Insmed

INSM stock →

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees

About Teva Pharmaceutical Industries

TEVA stock →

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees

INSM vs TEVA FAQ

Which is bigger, Insmed or Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.77B compared with $31.01B for Insmed (INSM).

Which stock has performed better over the past year, INSM or TEVA?

TEVA returned +62.04% over the past 12 months, compared with -28.89% for INSM (price return, excluding dividends). Past performance does not predict future results.

Are Insmed and Teva Pharmaceutical Industries in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons